Thermo Africos buys German genetic testing giant QIAGEN for $11.5 billion

On March 3rd ThermoSer announced its acquisition of GERMAN genetic testing giant QIAGEN NV for 39 euros per share (a total valuation of $11.5 billion), in a deal expected to be completed by the first half of 2021
The acquisition is based on four main considerations: expanding its product line of molecular diagnostic capabilities, including infectious disease testing, while Thermo Seiel has built a leading professional diagnostic capability, while QIAGEN has a strong presence in molecular diagnostics, and the combined company will accelerate the development of higher-specific, faster and more comprehensive testing; Immediately after the transaction is completed, it is expected that ThermoSer's adjusted earnings per share will be increased immediatelyIn addition, ThermoFri expects to achieve a total of $200 million in synergies in the third year after the deal is completed, including $150 million in cost synergies and $50 million in adjusted operating income
QIAGEN NV is a Dutch-based holding company with a major business in Germany and a global leader in Sample to Inight solutionsOn February 26, QIAGEN NV announced that it had shipped its newly developed QIAtat-Dx Respiratory Tester 2019-nCoV test kit to ChinaIt is reported that the new kit can detect the new coronavirus SARS-CoV-2, and in public health emergencies to provide rapid sample testing, while the QIAtat-Dx test system has also been shipped to Europe, Southeast Asia and the Middle East and other medical institutions
In 2019, QIAGEN NV net sales were $1.53 billion, including expendable kits and other revenue (89% of sales) and automation systems and instruments (11% of sales)Approximately 48% of net sales in 2019 came from the molecular diagnostics business and 52% from the life sciences business
Mr Thermo said the cash offer, at 39 euros a share, represented a 23 per cent premium to Monday's closing price, valuing the company at 10.4bn euros ($11.5bn), including 1.26bn euros in net debtThe deal will help Thermo Frisbee advance its precision medicine with a new molecular diagnostic service
According to the data, Thermo Seiair has been developing in China for 38 years, and its main client types include pharmaceutical and biological companies, hospitals and clinical diagnostic laboratories, universities, research institutes, environmental and industrial process control equipment manufacturers, etc
According to its annual report, Thermo Seiair's fourth-quarter revenue rose 5 percent to $6.83 billion and its full-year revenue rose 5 percent to $25.54 billionThe company's market capitalisation is now more than $110 billionThe industry believes that the company's rapid development can not be separated from the company in recent years crazy "buy and buy."
It is understood that thermos has had at least three acquisitions since 2019 aloneOn March 24, 2019, Thermo Fiseer Technologies announced its acquisition of Brammer Bio for $1.7 billion, which will expand its gene therapy business in the Virus Carrier Contract Development and Manufacturing Organization (CDMO); The announcement of the acquisition of QIAGEN by Thermo Seimer also shows the importance it attaches to the Chinese market In vitro diagnosis, as an area with potential for development in China's medical device industry, has also been recognized as the cornerstone of precision medicine in the industry.